NCT06916897View on ClinicalTrials.gov

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

February 22, 2025

Study Completion Date

February 22, 2025

Conditions
Healthy Subjects
Interventions
DRUG

sevasemten

single dose 10mg sevasemten administered orally

DRUG

Verapamil

multiple doses 240mg verapamil

Trial Locations (2)

68502

Celerion, Lincoln

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Edgewise Therapeutics, Inc.

INDUSTRY